Tec-Dara significantly improves PFS and OS compared to SoC in relapsed/refractory multiple myeloma
Published on 10 December 2025
Dr Luciano Costa speaks to ecancer about results from the MajesTEC-3 trial.
This trial shows that the BCMA×CD3 bispecific antibody teclistamab combined with daratumumab (Tec-Dara) delivers remarkable efficacy in relapsed/refractory multiple myeloma (RRMM).
With 1–3 prior lines of therapy, Tec-Dara significantly improved progression-free survival (PFS) and overall survival (OS) compared to standard triplet regimens (DPd/DVd), with 83.4% of patients alive and progression-free at 3 years.
Dr Costa explains that responses were deep and durable, including high rates of complete response (≥CR) and minimal residual disease (MRD) negativity.
The results conclude that Tec-Dara represents a potential new standard-of-care immunotherapy option for RRMM, even in early relapse.